Blog
RSS FeedPosted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April. ...
Posted by Michael Wonder on 11 Mar 2017
Institute for Clinical and Economic Review releases revised report on targeted immune modulators for treatment of rheumatoid arthritis
10 March 2017 - Analyses of evidence on comparative effectiveness raise questions about current step therapy protocols, while net prices for ...
Posted by Michael Wonder on 06 Mar 2017
ICER's final report on disease-modifying therapies for multiple sclerosis finds most drugs are over-priced in relation to benefits for patients; highlights need for stakeholder collaboration to address system issues
6 March 2017 - Key policy recommendations call on manufacturers to cease price increases and payers to ease coverage restrictions and ...
Posted by Michael Wonder on 04 Mar 2017
Public Summary Documents - PBAC November 2016 meeting
3 March 2017 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the PBAC November 2016 ...
Posted by Michael Wonder on 20 Feb 2017
The European Medicines Agency and publication of clinical study reports: a challenge for the US FDA
20 February 2017 - The US FDA has been the standard of drug regulation worldwide for decades. ...
Posted by Michael Wonder on 31 Jan 2017
Registration of new chemical entities in Australia (2016)
31 January 2017 - The TGA has published its annual summary for 2016. ...
Posted by Michael Wonder on 27 Jan 2017
Post-market review of ezetimibe – draft report
27 January 2017 - Public consultation on the draft Report to the PBAC of the post-market review of ezetimibe is ...
Posted by Michael Wonder on 27 Jan 2017
Institute for Clinical and Economic Review releases evidence report on disease-modifying therapies for multiple sclerosis, including daclizumab and ocrelizumab
26 January 2017 - Report finds alemtuzumab represents best long-term cost-effectiveness; prices for most drugs not well-aligned with added value ...
Posted by Michael Wonder on 22 Jan 2017
Call for feedback on a therapeutic review update of new second-line therapies for type 2 diabetes mellitus
20 January 2017 - Two draft science reports on new drugs for type 2 diabetes: second-line therapy : a therapeutic review ...
Posted by Michael Wonder on 22 Jan 2017
ICER releases draft evidence report on treatments for rheumatoid arthritis
20 January 2017 - Public comment period now open - comments accepted until 17 February. ...
Posted by Michael Wonder on 17 Jan 2017
Human medicines: highlights of 2016
17 January 2017 - 81 medicines recommended for approval, including 27 new active substances. ...
Posted by Michael Wonder on 06 Jan 2017
U.S. spending more on specialty drugs via Medicare
5 January 2017 - Federal spending on a Medicare program for people with high drug costs has ballooned over the ...
Posted by Michael Wonder on 06 Jan 2017
2016 financial year report from the Director
5 January 2017 - This letter is the Director's first annual report to various stakeholders. It summarises what Center have ...
Posted by Michael Wonder on 22 Dec 2016
EMA publishes EPAR for Venclyxto
22 December 2016 - The EMA has published an EPAR for AbbVie's new BCL inhibitor. ...
Posted by Michael Wonder on 18 Dec 2016
PBS expenditure and prescriptions for 2015-16
16 December 2016 - The PBS Expenditure and Prescriptions Report 2015-16 is now available. ...